Abstract
We compared interferon α (IFN-α) therapy with stem cell transplantation (SCT) for patients with chronic-phase chronic myelogenous leukemia in a multicenter prospective study to investigate the optimal indication and timing of SCT, especially from HLA-matched unrelated donors. Of 257 eligible patients, 145 patients who were younger than 50 years were assigned to the IFN-α cohort (n = 87) or the SCT cohort (n = 58), according to family donor availability. In the IFN-α cohort, 52 patients received IFN-α and chemotherapy (the IFN1 group), and 35 patients received an SCT from an unrelated donor (the U-SCT group). In the SCT cohort, 47 patients received an SCT from a related donor (the R-SCT group). In the IFN1 group, 88% of the patients achieved a complete hematologic response, and 33% achieved a complete cytogenetic response. At a median follow-up period of 53 months, the predicted 6-year survival rate was 72% in the IFN1 group, 81% in the R-SCT group, and 81% in the U-SCT group. When overall survival was evaluated for the IFN-α and R-SCT cohorts by intention to treat according to family donor availability, the 6-year survival rates were 76% and 84%, respectively. When the outcomes of the U-SCT and IFN1 groups were compared, the survival rate of U-SCT group patients was significantly better than for IFN1 group patients without a major cytogenetic response and seemed better for IFN1 group patients younger than 35 years. Therefore, U-SCT may be recommendable to patients who fail to achieve a major cytogenetic response in IFN-α therapy and to younger patients.
Similar content being viewed by others
References
Silver RT, Woolf SH, Hehlmann R, et al An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.Blood. 1999;94:1517–1536.
Ohnishi K, Ohno R, Tomonaga M, et al A randomize1d trial comparing interferon-alpha with busulfan for newly diagnosed chronic myelogenous leukemia in chronic phase.Blood. 1995;86:906–916.
Ohnishi K, Tomonaga M, Kamada N, et al A long term follow-up of a randomized trial comparing interferon-alpha with busulfan for chronic myelogenous leukemia: the Kouseisho Leukemia Study Group.Leuk Res. 1998;22:779–786.
Ohnishi K, Minami S, Ueda T, et al Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia: Kouseisho Leukemia Study Group.Int J Hematol. 2000;72:229–236.
Druker BJ, Talpaz M, Resta DJ, et al Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.N Engl J Med. 2001;344:1031–1037.
Kantarjian H, Sawyers C, Hochhaus A, et al, and the International STI571 CML Study Group. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia.N Engl J Med. 2002;346:645–652.
Kitajima K, Ishibashi M, Nagao T, Takahashi I, Kinoshita H. Clinical studies on the early diagnosis and treatment of blastic crisis of chronic myelogenous leukemia [in Japanese].Rinsho Ketsueki. 1972;13:560–568.
Talpaz M, Kantarjian H, McCredie KB, Keating MJ, Trujillo J, Gutterman J. Clinical investigation of human alpha interferon in chronic myelogenous leukemia.Blood. 1987;69:1280–1288.
Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia.Blood. 1984;63:789–799.
Hansen JA, Gooley TA, Martin PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia.N Engl J Med. 1998;338:962–968.
Japan Society for Hematopoietic Cell Transplantation. Annual report of nationwide survey 1999.JSHCT Monogr. 1999;2:68–79.
Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor: Japan Marrow Donor Program.N Engl J Med. 1998;339:1177–1185.
Italian Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia.N Engl J Med. 1994;330:820–825.
Italian Cooperative Study Group on Chronic Myeloid Leukemia and Italian Group for Bone Marrow Transplantation. Monitoring treatment and survival in chronic myeloid leukemia. JClin Oncol. 1999;17:1858–1868.
Gale RP, Hehlmann R, Zhang MJ, et al. Survival with bone marrow transplantation versus hydroxyurea or interferon for chronic myelogenous leukemia: the German CML Study Group.Blood. 1998; 91:1810–1819.
Hehlmann R, Heimpel H, Hasford J, et al. Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia: the German CML Study Group.Blood. 1994;84:4064–4077.
Weisdorf DJ, Anasetti C, Antin JH, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.Blood. 2002;99:1971–1977.
O’Brien SG, Guilhot F, Larson RA, et al, and the IRIS investigators. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.N Engl J Med. 2003;348:994–1004.
Hughes T, Kaeda J, Branford S, et al. Molecular responses to imatinib (STI571) or interferon + Ara-C as initial therapy for CML: results in the IRIS Study [abstract].Blood. 2002;100:93a-94a.
Graham SM, Jorgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro.Blood. 2002; 99:319–325.
Author information
Authors and Affiliations
Consortia
Corresponding author
About this article
Cite this article
Ohnishi, K., Ino, A., Kishimoto, Y. et al. Multicenter Prospective Study of Interferon α versus Allogeneic Stem Cell Transplantation for Patients with New Diagnoses of Chronic Myelogenous Leukemia. Int J Hematol 79, 345–353 (2004). https://doi.org/10.1532/IJH97.03160
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1532/IJH97.03160